<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03465436</url>
  </required_header>
  <id_info>
    <org_study_id>16900</org_study_id>
    <secondary_id>H8H-CD-LAHP</secondary_id>
    <secondary_id>COL-MIG-105</secondary_id>
    <secondary_id>2011-003229-88</secondary_id>
    <nct_id>NCT03465436</nct_id>
  </id_info>
  <brief_title>A Study of Lasmiditan on the Heart in Healthy Participants</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, 4-way Crossover Study to Compare the Effects on the Cardiac De- and Repolarization Duration as Well as Other Cardiac Safety Parameters of Two Doses of Oral Lasmiditan (100 mg and 400 mg) With Those of Moxifloxacin (400 mg) and Placebo in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CoLucid Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine how two doses of lasmiditan affected the heart in
      healthy participants. The study also evaluated how much lasmiditan got into the blood stream
      and how long it took the body to get rid of it. Information about side effects was collected.
      The study lasted a maximum of 46 days for each participant, not including screening.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 16, 2011</start_date>
  <completion_date type="Actual">December 20, 2011</completion_date>
  <primary_completion_date type="Actual">December 20, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Mean Fridericia-Corrected QT (QTcF) Values</measure>
    <time_frame>0.5 hours through 24 hours Postdose</time_frame>
    <description>Change from Baseline in Mean QTcF Values</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Mean Individually-Corrected QT (QTcI) Values</measure>
    <time_frame>0.5 hours through 24 hours Postdose</time_frame>
    <description>Change from Baseline in QTcI Values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Mean Cardiac Intervals: RR, PR, and QRS</measure>
    <time_frame>0.5 hours through 24 hours Postdose</time_frame>
    <description>ECGs were used to calculate cardiac intervals. The RR interval is the time between two R waves. The PR interval is the time between the beginning of the P wave to the beginning of the QRS complex. The QRS interval = deflections in the ECG, comprising Q, R, and S waves, which represent ventricular depolarization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Mean Heart Rate (HR)</measure>
    <time_frame>0.5 hours through 24 hours Postdose</time_frame>
    <description>Change from Baseline in Mean HR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in Electrocardiogram (ECG) Abnormalities</measure>
    <time_frame>0.5 hours through 24 hours Postdose</time_frame>
    <description>ECGs were assessed for morphology abnormalities for T-waves, U-waves, and other potential changes by a board-certified cardiologist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) of Lasmiditan</measure>
    <time_frame>Predose through 24 hours Postdose</time_frame>
    <description>Cmax of Lasmiditan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Time Curve (AUC) of Lasmiditan</measure>
    <time_frame>Predose through 24 hours Postdose</time_frame>
    <description>AUC of Lasmiditan</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Lasmiditan Dose 1 + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lasmiditan Dose 1 and placebo for moxifloxacin administered orally in one of four study periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lasmiditan Dose 2 + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lasmiditan Dose 2 and placebo for moxifloxacin administered orally in one of four study periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for lasmiditan and placebo for moxifloxacin administered orally in one of four study periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin + Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moxifloxacin and placebo for lasmiditan administered orally in one of four study periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasmiditan</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Lasmiditan Dose 1 + Placebo</arm_group_label>
    <arm_group_label>Lasmiditan Dose 2 + Placebo</arm_group_label>
    <other_name>LY573144</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Moxifloxacin + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Lasmiditan</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Placebo + Placebo</arm_group_label>
    <arm_group_label>Moxifloxacin + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Moxifloxacin</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Lasmiditan Dose 1 + Placebo</arm_group_label>
    <arm_group_label>Lasmiditan Dose 2 + Placebo</arm_group_label>
    <arm_group_label>Placebo + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index within 18.5 and 29.9 kilograms per meter squared (kg/mÂ²)

          -  In good physical and mental health as determined by the following:

               -  Complete medical history

               -  Complete physical examination

               -  Vital signs including blood pressure (supine and standing), heart rate (supine
                  and standing), respiratory rate, and temperature

               -  Standard 12-lead ECG (triplicate ECG), followed by a 24-hour Holter ECG for
                  arrhythmia monitoring

               -  Clinical laboratory tests

        Exclusion Criteria:

          -  Any of the following cardiac abnormalities on safety screening ECG:

               -  QTcF interval &gt;430 milliseconds (ms) for males, &gt;450 ms for females

               -  Unusual T wave morphology or flattened low voltage T waves

               -  PR interval &gt;240 ms or &lt;110 ms

               -  Second-degree or third-degree atrioventricular block

               -  ECG evidence of complete left or right bundle branch block

               -  Intraventricular conduction delay or QRS duration &gt;110 ms

               -  Supine resting heart rate &lt;45 beats per minute (bpm) or &gt;90 bpm

               -  Pathological Q-waves

               -  Evidence of ventricular pre-excitation

          -  Participants with a history of syncope, cardiac arrest, cardiac arrhythmia or torsade
             de pointes, or structural heart disease

          -  Participants with a family history of Long QT syndrome

          -  History of allergic hypersensitivity to lasmiditan or any component of the
             formulations

          -  History or current evidence of abuse of any drug substance, licit or illicit,
             including alcohol; a positive urine screen for drugs of abuse

          -  Participants with a history of postural hypotension or fainting

          -  Participant is not able to understand and comply with study requirements, instructions
             and study restrictions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2018</study_first_submitted>
  <study_first_submitted_qc>March 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2018</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

